Frontiers in endocrinologyOct 7, 2024

Possible roles of glucagon-like peptide-1 receptor activators in cancers

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jan 20, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may influence tumor occurrence and development.

GLP-1RAs are recognized for lowering blood sugar and reducing weight.
They may also have effects on inflammation and blood lipid levels.
Evidence suggests GLP-1RAs could impact cell proliferation and survival.
The potential relationship between GLP-1RAs and neoplastic disease prognosis is explored.

Simplified

Glucagon-like peptide-1 receptor agonist (GLP-1RA), a novel hypoglycemic agent for the treatment of type 2 diabetes, has well-known effects such as lowering blood sugar, ameliorating inflammation, reducing weight, and lowering blood lipids. It has also been shown that it can influence the proliferation and survival of cells and has a certain effect on the prognosis of some neoplastic diseases. In this study, the potential effects of GLP-1RAs on the occurrence and development of tumors were reviewed to provide new ideas for the prevention and treatment of tumors in patients.

Full Text

Full text is available at the source.

View Full Text ↗

Possible roles of glucagon-like peptide-1 receptor activators in cancers

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the glp-1 therapies brief